Search
Search Results
-
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
BackgroundTeclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma...
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
IntroductionTeclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of...
-
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
IntroductionPatients with triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM) have a poor prognosis and limited treatment options....
-
Real-world analysis of teclistamab in 123 RRMM patients from Germany
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the...
-
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
BackgroundTeclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell–mediated cytotoxicity of...
-
Teclistamab: First Approval
Teclistamab (TECVAYLI ® ), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and...
-
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Immunotherapies have significantly improved outcomes in patients with multiple myeloma yet maintaining a durable response in heavily pretreated...
-
Therapeutic progress in relapsed/refractory multiple myeloma
Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in...
-
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients....
-
Nirogacestat: First Approval
Nirogacestat (OGSIVEO™) is an oral, selective, reversible, small molecule γ-secretase inhibitor developed by SpringWorks Therapeutics, Inc....
-
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led...
-
-
ASH highlights 2022—multiple myeloma
The 64th annual meeting was held in New Orleans, Louisiana from December 10–13, 2022. More than 150 abstracts concerning multiple myeloma have been...
-
The emerging therapeutic landscape of relapsed/refractory multiple myeloma
From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of...
-
Bispecific antibodies for multiple myeloma: past, present and future
Despite the development of various therapeutic agents, multiple myeloma remains incurable. Recently, T-cell redirected immunotherapy has become a...
-
Bispecific Antibodies for the Treatment of Multiple Myeloma
Purpose of ReviewAdvances in multiple myeloma therapies have greatly improved outcomes for patients living with the disease, although to date there...
